乌司他丁联合生长抑素对重症急性胰腺炎患者肠黏膜功能及腹内压的影响

Effects of Ulinastatin Combined with Somatostatin on Intestinal Mucosa and Intra-abdominal Pressure of Patients with Severe Acute Pancreatitis

目的:探讨乌司他丁联合生长抑素对重症急性胰腺炎(SAP)患者肠黏膜功能及腹内压的影响。方法:选取2019年2月~2021年2月期间本院收治的150例SAP患者为研究对象,随机分为生长抑素组和联合组,每组各75例。生长抑素组在常规治疗基础上增加生长抑素治疗,联合组在生长抑素组治疗基础上增加乌司他丁治疗,比较两组的临床疗效、炎症因子指标、肠黏膜功能、腹内压、实验室相关指标和并发症情况。结果:联合组治疗总有效率高于生长抑素组(P<0.05);联合组白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和高敏C反应蛋白(hs-CRP)水平均低于生长抑素组(P<0.05);联合组D-乳酸、二胺氧化酶(DAO)水平和腹内压均低于生长抑素组(P<0.05);联合组肌酐、胆红素和总白细胞计数水平低于生长抑素组(P<0.05),血小板计数高于生长抑素组(P<0.05);联合组治疗后并发症总发生率低于生长抑素组(P<0.05)。结论:乌司他丁联合生长抑素治疗SAP效果显著,可有效减轻患者炎症反应,保护肠黏膜屏障功能,缓解症状,保护患者器官功能,减少并发症。

Objective:To investigate the effects of ulinastatin combined with intestinal mucosa and intraabdominal pressure of patients with severe acute pancreatitis(SAP).Methods:A total of 150 patients with severe acute pancreatitis admitted to our hospital from February 2019 to February 2021 were selected as research subjects and randomly divided into the somatostatin group and the combined group,75 cases in each group.The somatostatin group was treated with somatostatin,and the combined group was treated with ulinastatin combined with somatostatin.Clinical efficacy,inflammatory factor indicators,gastrointestinal mucosal function,intra-abdominal pressure,laboratory-related indicators and the occurrence of complications were compared between the two groups.Results:The total effective rate in the combined group was higher than that in the somatostatin group(P<0.05).The levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and high-sensitivity C-reactive protein(hs-CRP)in the combined group were significantly lower than those in the somatostatin group(P<0.05).The levels of D-lactic acid,DAO and intra-abdominal pressure in the combined group were significantly lower than those in the somatostatin group(P<0.05).The levels of creatinine,bilirubin and total white blood cell count in the combined group were significantly lower than those in the somatostatin group(P<0.05),and the platelet count was significantly higher than that in the somatostatin group(P<0.05).The total incidence of complications in the combined group was significantly lower than that in the somatostatin group(P<0.05).Conclusion:Ulinastatin combined with somatostatin in the treatment of SAP has significant effects,which can reduce the inflammatory response of patients,protect the gastrointestinal mucosal barrier function,relieve symptoms,protect the organ function of patients and reduce the incidence of complications.